Status:
UNKNOWN
Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer
Lead Sponsor:
Shanghai Chest Hospital
Conditions:
SCLC
Anlotinib
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This is a phase II, open-label, single center study, aiming to investigate safety and efficacy of etoposide and carboplatin (administered intravenously) in combination with anlotinib (administered ora...
Detailed Description
Lung cancer can be divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), of which SCLC accounts for about 15%-20%.Because of the high degree of malignancy of SCLC, patient...
Eligibility Criteria
Inclusion
- According to the 8th edition of the AJCC/UICC TNM staging system for NSCLC, patients with extensive stage SCLC confirmed by histology or cytology and are confirmed to have at least one measurable lesion according to RECIST 1.1.
- Without active brain metastasis
- Previously treated with ICIs with progressive disease.
- Age ≥18 years and ≤75 years;
- ECOG PS score: 0 to 1
- The main organs function is normal, that is, the following criteria met: good hematopoietic function, defined as absolute neutrophil count ≥1.5×109 /L, platelet count≥100 ×109 /L, hemoglobin ≥90g/L \[no blood transfusion or no erythropoietin (EPO) dependence within 7 days before enrollment\]; biochemical test results should meet the following criteria: BIL \< 1.25 times the upper limit of normal value (ULN); ALT and AST \< 2.5 × ULN; in case of liver metastases, ALT and AST \< 5 × ULN; Cr ≤1.5×ULN or creatinine clearance (CCr) ≥60ml/min; Coagulation function is good, INR and PT ≤1.5 times ULN; if the subject is receiving anticoagulant treatment, PT should be within the prescribed range of use of anticoagulant drugs;
- Women of child-bearing age should agree to take contraceptive measures (such as intrauterine devices, contraceptives or condoms) during the study and within 6 months after the study; non-breast-feeding patients whose serum or urinary pregnancy test should be negative; male patients should agree to take contraceptive measures during the study and within 6 months after the study.
- Patients are voluntarily enrolled into the study, sign the informed consent form and have good compliance.
Exclusion
- Subjects with active CNS metastases are excluded.
- Non-small cell lung cancer.
- With obvious hemorrhage symptom
- Patients with many factors affecting oral medication, such as dysphagia, gastrointestinal resection, chronic diarrhea and intestinal obstruction.
- Combined with other tumors at the time of initial diagnosis.
- Patients who have previously participated in other clinical trials and have not yet terminated the trial.
- Patients who have acute infection that difficult to control.
Key Trial Info
Start Date :
May 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT04684017
Start Date
May 1 2019
End Date
January 1 2022
Last Update
December 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Chest hospital
Shanghai, Shanghai Municipality, China, 200030